451 related articles for article (PubMed ID: 24909093)
1. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
2. Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Norjavaara E; Ericsson H; Sjöberg F; Leonsson-Zachrisson M; Sjöstrand M; Morrow LA; Hompesch M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3319-25. PubMed ID: 22723318
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E
Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Ericsson H; Röshammar D; Wollbratt M; Heijer M; Persson M; Ueda S; Leonsson-Zachrisson M; Norjavaara E
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):765-77. PubMed ID: 22943931
[TBL] [Abstract][Full Text] [Related]
5. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Wilding JP; Leonsson-Zachrisson M; Wessman C; Johnsson E
Diabetes Obes Metab; 2013 Aug; 15(8):750-9. PubMed ID: 23464532
[TBL] [Abstract][Full Text] [Related]
6. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Kiyosue A; Hayashi N; Komori H; Leonsson-Zachrisson M; Johnsson E
Diabetes Obes Metab; 2013 Oct; 15(10):923-30. PubMed ID: 23522182
[TBL] [Abstract][Full Text] [Related]
7. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
8. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
Choudhary P; Lonnen K; Emery CJ; MacDonald IA; MacLeod KM; Amiel SA; Heller SR
Diabet Med; 2009 Jul; 26(7):665-72. PubMed ID: 19573114
[TBL] [Abstract][Full Text] [Related]
9. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Farngren J; Persson M; Ahrén B
Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
[TBL] [Abstract][Full Text] [Related]
10. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
11. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
12. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
14. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
[TBL] [Abstract][Full Text] [Related]
15. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
17. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
19. Counterregulatory hormones in insulin-treated diabetic patients admitted to an accident and emergency department with hypoglycaemia.
Hvidberg A; Christensen NJ; Hilsted J
Diabet Med; 1998 Mar; 15(3):199-204. PubMed ID: 9545120
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
